Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Samuel Anthony Lachlan HallGareth S BurnsDespina AnagnostouSara VogrinVijaya SundararajanDilip RatnamMiriam T LevyJohn S LubelAmanda J NicollSimone I StrasserWilliam SievertPaul V DesmondMeng C NguPeter AngusMarie SinclairChristopher MeredithGail MatthewsPeter A RevillKathy JacksonMargaret LittlejohnD Scott BowdenStephen A LocarniniKumar VisvanathanAlexander J ThompsonPublished in: Alimentary pharmacology & therapeutics (2022)
Virological reactivation was very common after stopping NA therapy and occurred earlier after stopping TDF versus ETV. The majority of patients had ALT <2× ULN at week 96, but only one-third achieved disease remission and HBsAg loss was rare. Very low HBsAg levels at baseline were uncommon but predicted for HBsAg loss and disease remission.